| Theme | Clinical Diagnosis and Management of Gastric Cancer 2019 -- Current Status and Issues | |
|---|---|---|
| Title | Advances in the Chemotherapy of Gastric Cancer | |
| Publish Date | 2019/10 | |
| Author | Masashi Ishikawa | National Cancer Center Hospital, Gastrointestinal Medical Oncology |
| Author | Narikazu Boku | National Cancer Center Hospital, Gastrointestinal Medical Oncology |
| [ Summary ] | Currently, a combination of fluoropyrimidine and platinum is recommended as the first‒line chemotherapy treatment for unresectable advanced/recurrent gastric cancer and trastuzumab is added for HER2 (human epithelial growth factor receptor type 2) positive gastric cancer. The 5th edition of the guidelines for gastric cancer treatment have been revised and classified chemotherapy regimens including second‒ and third‒chemotherapy into either "recommended" or "conditionally recommended". As for the perioperative chemotherapy for resectable gastric cancer, one year of S‒1 chemotherapy for pStageII and III and half year of CapeOX chemotherapy is currently recommended for pStageⅢ after curative resection. DS (DTX+S-1) regimen will be added as the standard postoperative chemotherapy for pStageIII from the results of the JACCRO GC‒07 trial. In addition, immune checkpoint inhibitors have shown favorable results in the KEYNOTE‒059 test and ATTRACTION‒04 trials and it is expected that they will be added as a new standard first‒line chemotherapy in the near future. |
|